AN OPEN-LABEL MULTICENTER OBSERVATIONAL STUDY OF THE EFFICACY, TOLERABILITY, AND SAFETY OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG AMTOLMETIN GUACIL IN PATIENTS WITH KNEE OSTEOARTHRITIS AND DYSPEPSIA

Objective: to investigate the efficacy and tolerability of amtolmetin guacil (AMG; Niselat®, Dr. Reddy's Laboratories Ltd, India) versus previous therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with knee osteoarthritis (OA) and signs of dyspepsia.

Subjects and methods. The open-label observational study included 220 patients aged 30–65 years who suffered from knee OA and intense pain during NSAID intake and had symptoms of dyspepsia in the absence of contraindications to the use of AMG. Among the comorbidities that generally occurred in 68% of the patients, there was a preponderance of hypertension (42%), lower extremity varicose veins (6.4%), and diabetes mellitus (6%). Treatment efficacy was evaluated using three domains of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), by also taking into account pain intensity and general health assessment on the visual analogue scale. A Severity of Dyspepsia Assessment (SODA) scale was used to rate dyspepsia.

Results and discussion. AMG had a marked analgesic effect confirmed by 40% or more pain reduction that occurred in 72.5% of the patients. The high analgesic effect of AMG was confirmed by a statistically significant (p <0.001) reduction in the WOMAC index (pain and stiffness) and by an increase in functional activity. There was a significant decrease in painless and painful signs of dyspepsia, as well as positive changes in the measures “overall assessment of dyspepsia severity” (p < 0.001) and “satisfaction with treatment”. Overall assessment of AMG tolerability was only positive: excellent (33%), good (56%), and satisfactory (11%). There were no serious adverse events (AE). AE were graded as moderate and mild in 8 and 82% of cases, respectively. AE were recorded in 7.7% of the patients.

Conclusion. The findings suggest that AMG offers good prospects for knee OA treatment.

1. Glyn-Jones S, Palmer AJR, Agricola R, et al. Osteoarthritis. Lancet. 2015 Jul 25;386(9991):376-87. doi: 10.1016/S0140-6736(14)60802-3

2. Woolf AD, Pfleger B. Durden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646-56.

3. Эрдес ШФ, Фоломеева ОМ. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. Научно-практическая ревматология. 2007;45(4):4- 10 [Erdes SF, Folomeeva OM. Rheumatic diseases and disability of Russian Federation adult population. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(4):4-9 (In Russ.)]. doi: 10.14412/1995-4484-2007-4-9

4. Фоломеева ОМ, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяции взрослого населения России и США. Научно- практическая ревматология 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13 (In Russ.)]. doi: 10.14412/1995-4484-2008-529

5. National Clinical Guideline Centre. Osteoarthritis. Care and management in adults. NICE Clinical Guideline 177. London, UK: National Institute for Health and Care Excellence. February 2014. Available from: http://www.nice.org.uk/guidance/CG177

6. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465-74. doi: 10.1002/acr.21596

7. Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253-63. doi: 10.1016/j.semarthrit.2014.05.014

8. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22:363-88. doi: 10.1016/j.joca.2014.01.003

9. Scarpifnato C, Lanas A, Blandizzi C, et al.; for International NSAIS Consensus Group. Safe rescribing of non-steroidal antiinflammatory drugs in patients with osteoarthritis – an expert consensus addresing benefits aswell as gastrointestinal and cardiovascular risk. BMC Medicine. 2015;13:55. doi: 10.1186/s12916-015-0285-8

10. Vane JR. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol. 2000;51:573-86.

11. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and heart. Circulation. 2014;129:907-16. doi: 10.1161/CIRCULATIONAHA. 113.004480

12. Rabeneck L, Wristers K, Goldstein JL, et al. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. The Amer J Gastroenterol. 2002;97:32-9. doi: 10.1111/j.1572-0241.2002.05419.x

13. Ofman JJ, MacLean CH, Straus WL, et al. Meta-analysis of dyspepsia and non-steroidal anti-inflammatory drugs. Arthritis Rheum. 2003;49:508-18. doi: 10.1002/art.11192

14. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;15 Suppl:18-24.

15. Spiegel BMR, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with coxibs vs NSAID+OOI: a meta-analysis. Amer J Med. 2006;119, 448.e27-36. doi: 10.1016/j.amjmed.2005.11.020

16. Jajic Z, Malaise M, Nekam K, et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:809-18.

17. Lazzaroni M, Anderloni A, Bianchi Porro G. The effects on gastroduodenal mucosa of a new nonsteroidal anti-inflammatory drug, amtolmetin-guacyl, versus piroxicam in healthy volunteers: a short-term, double blind, endoscopically controlled study. Euro J Gastroenterol Hepatol. 2001;13:833-9. doi: 10.1097/00042737-200107000-00012

18. Montrone F, Santandrea S, Caruso I, et al. Amtolmetin guacyl versus piroxicam in patients with osteoarthritis. J Int Med Res. 2000;28:91-100. doi: 10.1177/147323000002800204

19. Bianchi Porro G, Montrone F, Lazzaroni M, et al. Clinical and gastroscopic evaluation of amtolmetin guacyl versus diclofenac in patients with rheumatoid arthritis. Italian J Gastroenterol Hepatol. 1999;31:378-85.

20. Garg A, Shoeb A, Moodahadu LS, et al. Amtolmetin: a reaprasal of NSAID with gastroprotection. Arthritis. 2016;2016:7103705. doi: 10.1155/2016/7103705. Epub 2016 Mar 22.

21. Pisano C, Grandi D, Morini G, et al. Gastrosparing effect of new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Digestive Dis Sci. 1999;44:713-24. doi: 10.1023/A:1026653623516

22. Coruzzi G, Coppelli G, Spaggiari A, et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates gastric nitric oxide synthase. Dig Liv Dis. 2002;34:403-10. doi: 10.1016/S1590-8658(02)80037-8

23. Rabeneck L, Cook KF, Wristers K, et al. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia- related health. J Clin Epid. 2001;54:755-65. doi: 10.1016/S0895-4356(00)00365-6

24. Konturek SJ, Brzozowski T, Majka J, et al. Implications of nitric oxide in the action of cytoprotective drugs on gastric mucosa. J Clin Gastroenter. 1993;17 Suppl 1:S140-5. doi: 10.1097/00004836-199312001-00025

25. Szlachcic A, Krzysiek-Maczka G, Pajdo R, et al. The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage. Curr Pharm Des. 2013;19:90-7.

26. Wallace JL, Miller MJS. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology. 2000;119:512-20. doi: 10.1053/gast.2000.9304

27. Koc E, Kü cü kgü zel SG. Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs. Med Chemistry. 2009;9:611-9. doi: 10.2174/138955709788167556

28. Wallace JL. NSAID gastropathy and entheropathy: distict pathogenesis likely necessistates distict prevention strategy. Brit J Pharmacol. 2012;165:67-74. doi: 10.1111/j.1476-5381.2011.01509.x

29. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol. 1999;231 Suppl:48-54. doi: 10.1080/003655299750025264

30. Sostres C, Gargallo CJ, Lanas A. Non-steroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3. doi: 10.1186/ar4175

31. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut. 1999;45 Suppl 2:II37-42. doi: 10.1136/gut.45.2008.ii37

32. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Gut. 1987;28:527-32. doi: 10.1136/gut.28.5.527

33. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of non- steroidal anti-inflammatory drug treatment in rheumatoidarthritis. Arch Intern Med. 1996;156:1530-6. doi: 10.1001/archinte.1996.00440130066007